Leap Therapeutics Inc (LPTX)

$0.48 +0.01 (2.33%)
Market Cap 19.83M
Revenue (ttm) 0.00
Net Income (ttm) -67.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 476,400
Avg Vol 4,084,750
Day's Range N/A - N/A
Shares Out 41.44M
Stochastic %K 19%
Beta -0.05
Analysts Hold
Price Target $1.25

Company Profile

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 714 0360
Address:
47 Thorndike Street, Suite B1-1, Cambridge, United States
deano361
deano361 Oct. 25 at 12:12 AM
$LPTX - **Strategic Optics**: Proposing the split *now* leverages the positive sentiment from the PIPE and digital asset pivot to secure shareholder votes (December 15 meeting). The board likely wants the tool ready in case market conditions worsen. In short, the split is a safety net. The board’s not obligated to act unless the stock stays below $1, risking delisting. This aligns with biotech precedents—e.g., Cassava Sciences (SAVA) proposed a similar discretionary split in 2024 but didn’t execute it after a price rally.
1 · Reply
Slambucket
Slambucket Oct. 24 at 9:25 PM
$LPTX - To borrow a quote from the CEO Doug Onsi, you’ll want to read the proxy in its entirety: https://investors.leaptx.com/node/10296/html
3 · Reply
deano361
deano361 Oct. 24 at 2:25 PM
$LPTX what’s coming in some form . Research it . What financial rail $XRP.X Or $BTC.X or other will take us past $1 imo easily https://x.com/vivo_power/status/1927768331395764700?s=46&t=5ZlRqS0Wfi9BNWKligb-Qw
0 · Reply
Tom678
Tom678 Oct. 24 at 1:22 PM
$LPTX
0 · Reply
FreeWill1959
FreeWill1959 Oct. 24 at 8:10 AM
$LPTX Who can explain to me this stupid, senseless trading of 1 (!!!) share of this stock at 4:02am at $0.4535?!?!
1 · Reply
MTN52C
MTN52C Oct. 24 at 6:04 AM
$LPTX Get in BYND tomorrow (Friday) if we stay 2.50 - $3+ we will have a SQUEEZE on Monday. Puts are forced to cover and price will sky rocket highly possible double digits!!!!!
0 · Reply
deano361
deano361 Oct. 23 at 11:06 PM
$LPTX winkle bros https://x.com/pete_rizzo_/status/1981185557578326501?s=46&t=5ZlRqS0Wfi9BNWKligb-Qw
0 · Reply
IwM
IwM Oct. 23 at 10:30 PM
$LPTX falling wedge. Winklevoss coming to break this wide open with their billionaire buddies 🤷🏼‍♂️
1 · Reply
deano361
deano361 Oct. 23 at 10:28 PM
$LPTX a/h jump ?
0 · Reply
deano361
deano361 Oct. 23 at 3:58 PM
$LPTX clarity act coming ! Let’s reveal your digital asset strategy. Hope it’s like vivo power $XRP.X and add in $BTC.X on balance sheet from the bros ! If so no price is off the table !! I’m on this to see what the Bros bring .
0 · Reply
Latest News on LPTX
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

Oct 20, 2025, 7:00 AM EDT - 5 days ago

Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Oct 9, 2025, 7:00 AM EDT - 16 days ago

Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Oct 6, 2025, 9:00 AM EDT - 19 days ago

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

Sep 25, 2025, 7:00 AM EDT - 4 weeks ago

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

Leap Therapeutics Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 7:00 AM EDT - 2 months ago

Leap Therapeutics Reports Second Quarter 2025 Financial Results

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

Jun 23, 2025, 7:00 AM EDT - 4 months ago

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

Leap Therapeutics Reports First Quarter 2025 Financial Results

May 13, 2025, 7:00 AM EDT - 5 months ago

Leap Therapeutics Reports First Quarter 2025 Financial Results

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Apr 25, 2025, 1:00 PM EDT - 6 months ago

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Apr 15, 2025, 7:00 AM EDT - 6 months ago

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Mar 31, 2025, 1:42 PM EDT - 7 months ago

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Mar 26, 2025, 1:29 PM EDT - 7 months ago

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 26, 2025, 7:05 AM EDT - 7 months ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Mar 26, 2025, 7:00 AM EDT - 7 months ago

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Jan 28, 2025, 7:00 AM EST - 9 months ago

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Jan 6, 2025, 7:01 AM EST - 10 months ago

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:00 AM EST - 10 months ago

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 11 months ago

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Second Quarter 2024 Financial Results

Leap Therapeutics Reports First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports First Quarter 2024 Financial Results

Leap Therapeutics Announces $40 Million Private Placement

Apr 11, 2024, 8:30 AM EDT - 1 year ago

Leap Therapeutics Announces $40 Million Private Placement

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Jan 16, 2024, 5:05 PM EST - 1 year ago

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Jan 2, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Dec 11, 2023, 4:05 PM EST - 2 years ago

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Nov 21, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Leap Therapeutics to Participate at Upcoming Investor Conferences

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics to Participate at Upcoming Investor Conferences

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Jul 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split

Jun 20, 2023, 12:30 PM EDT - 2 years ago

Leap Therapeutics Announces Reverse Stock Split

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

May 25, 2023, 5:10 PM EDT - 2 years ago

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Leap Therapeutics Reports First Quarter 2023 Financial Results

May 15, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports First Quarter 2023 Financial Results

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Apr 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

Mar 16, 2023, 4:05 PM EDT - 2 years ago

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

Leap Therapeutics Acquires Flame Biosciences

Jan 17, 2023, 8:00 AM EST - 3 years ago

Leap Therapeutics Acquires Flame Biosciences

Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference

Jan 11, 2023, 7:00 AM EST - 3 years ago

Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference

Nov 21, 2022, 7:00 AM EST - 3 years ago

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference

Leap Therapeutics Reports Third Quarter 2022 Financial Results

Nov 14, 2022, 7:00 AM EST - 3 years ago

Leap Therapeutics Reports Third Quarter 2022 Financial Results

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Nov 7, 2022, 8:05 AM EST - 3 years ago

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Oct 17, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Oct 12, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference

deano361
deano361 Oct. 25 at 12:12 AM
$LPTX - **Strategic Optics**: Proposing the split *now* leverages the positive sentiment from the PIPE and digital asset pivot to secure shareholder votes (December 15 meeting). The board likely wants the tool ready in case market conditions worsen. In short, the split is a safety net. The board’s not obligated to act unless the stock stays below $1, risking delisting. This aligns with biotech precedents—e.g., Cassava Sciences (SAVA) proposed a similar discretionary split in 2024 but didn’t execute it after a price rally.
1 · Reply
Slambucket
Slambucket Oct. 24 at 9:25 PM
$LPTX - To borrow a quote from the CEO Doug Onsi, you’ll want to read the proxy in its entirety: https://investors.leaptx.com/node/10296/html
3 · Reply
deano361
deano361 Oct. 24 at 2:25 PM
$LPTX what’s coming in some form . Research it . What financial rail $XRP.X Or $BTC.X or other will take us past $1 imo easily https://x.com/vivo_power/status/1927768331395764700?s=46&t=5ZlRqS0Wfi9BNWKligb-Qw
0 · Reply
Tom678
Tom678 Oct. 24 at 1:22 PM
$LPTX
0 · Reply
FreeWill1959
FreeWill1959 Oct. 24 at 8:10 AM
$LPTX Who can explain to me this stupid, senseless trading of 1 (!!!) share of this stock at 4:02am at $0.4535?!?!
1 · Reply
MTN52C
MTN52C Oct. 24 at 6:04 AM
$LPTX Get in BYND tomorrow (Friday) if we stay 2.50 - $3+ we will have a SQUEEZE on Monday. Puts are forced to cover and price will sky rocket highly possible double digits!!!!!
0 · Reply
deano361
deano361 Oct. 23 at 11:06 PM
$LPTX winkle bros https://x.com/pete_rizzo_/status/1981185557578326501?s=46&t=5ZlRqS0Wfi9BNWKligb-Qw
0 · Reply
IwM
IwM Oct. 23 at 10:30 PM
$LPTX falling wedge. Winklevoss coming to break this wide open with their billionaire buddies 🤷🏼‍♂️
1 · Reply
deano361
deano361 Oct. 23 at 10:28 PM
$LPTX a/h jump ?
0 · Reply
deano361
deano361 Oct. 23 at 3:58 PM
$LPTX clarity act coming ! Let’s reveal your digital asset strategy. Hope it’s like vivo power $XRP.X and add in $BTC.X on balance sheet from the bros ! If so no price is off the table !! I’m on this to see what the Bros bring .
0 · Reply
Whales22
Whales22 Oct. 23 at 7:30 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $BNAI $LPTX $ANRO $BEEM Watchlist/
1 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 22 at 8:03 PM
🚀 New Signal ✅ 💊 $LPTX 🗓️ Oct 22, 2025 💵 Entry: $0.4556 🎯 Target (Opt.): $0.5369 (+17.84%) 👉 FREE TRIAL! Check bio.
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 22 at 7:03 PM
🚀 New Signal ✅ 💊 $LPTX 🗓️ Oct 22, 2025 💵 Entry: $0.4396 🎯 Target (Opt.): $0.5236 (+19.11%) 👉 FREE TRIAL! Check bio.
0 · Reply
Aurum81
Aurum81 Oct. 22 at 5:11 PM
$LPTX This thing beats everything... it's unbelievable that just a few days ago we were at 0.98...
0 · Reply
itsStocksOver
itsStocksOver Oct. 22 at 5:02 PM
$LPTX wtf 🤢
0 · Reply
deano361
deano361 Oct. 22 at 2:57 PM
$LPTX brothers share you digital strategy before clarity act passes
1 · Reply
elchulo58
elchulo58 Oct. 22 at 2:19 PM
$LPTX still looks a little bullish…we shall see…
0 · Reply
IwM
IwM Oct. 22 at 2:05 PM
$LPTX Winklevoss ain’t done….we shall see
0 · Reply
stocks4growth
stocks4growth Oct. 22 at 1:53 PM
$LPTX slowly bleeding out...
0 · Reply
Bellz22
Bellz22 Oct. 22 at 12:31 AM
$LPTX f*ck sakes
0 · Reply
itsStocksOver
itsStocksOver Oct. 22 at 12:10 AM
$LPTX that overnight drop 🤢🤢
0 · Reply
Redboal
Redboal Oct. 21 at 8:16 PM
$LPTX I see a lot of newbies here who thought the stock would move higher on news 🤣 welcome to the Onsi Value Destruction club. He is one of a kind 🥳
0 · Reply